Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Yap

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
The Lancet. Gastroenterology & Hepatology|November 12, 2017
Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trialPhilip Noel Newsome, Richard Fox, Andrew L King, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 26, 2018
Development of Clinical Criteria for Functional Assessment to Predict Primary Nonfunction of High-Risk Livers Using Normothermic Machine PerfusionHynek Mergental, Barnaby T F Stephenson, Richard W Laing, et al.
Blood|October 28, 2017
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamideClaire N Harrison, Adam J Mead, Anesh Panchal, et al.
Immunity|March 2, 2024
Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidaseJulia Lederhofer, Yaroslav Tsybovsky, Lam Nguyen, et al.
Cell Reports. Medicine|December 6, 2023
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trialJenna H Rannikko, Loic Verlingue, Maria de Miguel, et al.
BMC Medicine|October 2, 2025
Practical guidance for conducting high-quality and rapid interim analyses in adaptive clinical trialsHelen Mossop, Zoë Walmsley, Nina Wilson, et al.
BMC Medicine|October 26, 2021
Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials projectNina Wilson, Katie Biggs, Sarah Bowden, et al.
BMC Medicine|July 5, 2023
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE studyOlga Solovyeva, Munyaradzi Dimairo, Christopher J Weir, et al.
Nature Medicine|June 27, 2025
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trialSusana Banerjee, Matthew G Krebs, Alastair Greystoke, et al.
Investigational New Drugs|May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerKhobe Chandran, Christina Guo, Simon Pacey, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
The Lancet. Gastroenterology & Hepatology|November 12, 2017
Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trialPhilip Noel Newsome, Richard Fox, Andrew L King, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 26, 2018
Development of Clinical Criteria for Functional Assessment to Predict Primary Nonfunction of High-Risk Livers Using Normothermic Machine PerfusionHynek Mergental, Barnaby T F Stephenson, Richard W Laing, et al.
Blood|October 28, 2017
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamideClaire N Harrison, Adam J Mead, Anesh Panchal, et al.
Immunity|March 2, 2024
Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidaseJulia Lederhofer, Yaroslav Tsybovsky, Lam Nguyen, et al.
Cell Reports. Medicine|December 6, 2023
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trialJenna H Rannikko, Loic Verlingue, Maria de Miguel, et al.
BMC Medicine|October 2, 2025
Practical guidance for conducting high-quality and rapid interim analyses in adaptive clinical trialsHelen Mossop, Zoë Walmsley, Nina Wilson, et al.
BMC Medicine|October 26, 2021
Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials projectNina Wilson, Katie Biggs, Sarah Bowden, et al.
BMC Medicine|July 5, 2023
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE studyOlga Solovyeva, Munyaradzi Dimairo, Christopher J Weir, et al.
Nature Medicine|June 27, 2025
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trialSusana Banerjee, Matthew G Krebs, Alastair Greystoke, et al.
Investigational New Drugs|May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerKhobe Chandran, Christina Guo, Simon Pacey, et al.
Pageof 9